[HTML] mdpi.com

[HTML][HTML] Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant Acinetobacter baumannii with Polymyxin-Based Combinations

M Wences, ER Wolf, C Li, N Singh, N Bah, X Tan… - Antibiotics, 2022 - mdpi.com
Carbapenem-resistant Acinetobacter baumannii (CRAB) can cause serious infections that
are associated with high mortality rates. During the course of an infection, many CRAB …
被引用次数：6 相关文章 所有 8 个版本
[HTML] springer.comFull View

[HTML][HTML] Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter …

C Lyu, Y Zhang, X Liu, J Wu, J Zhang - BMC Infectious Diseases, 2020 - Springer
Background The prevalence of infections due to carbapenem-resistant Acinetobacter
baumannii (CRAB) is on the rise worldwide. Polymyxins are considered as last-resort drugs …
被引用次数：30 相关文章 所有 8 个版本
[HTML] mdpi.com

[HTML][HTML] Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaOXA-23-harboring CRAB in In Vitro PK/PD Model

X Qu, X Bian, Y Chen, J Hu, X Huang, Y Wang, Y Fan… - Molecules, 2022 - mdpi.com
Polymyxin-based combination therapy is commonly used to treat carbapenem-resistant
Acinetobacter baumannii (CRAB) infections. In the present study, the bactericidal effect of …
被引用次数：4 相关文章 所有 11 个版本
[HTML] oup.com

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii

JR Lenhard, JB Bulitta, TD Connell… - Journal of …, 2016 - academic.oup.com
Objectives The pharmacodynamics of polymyxin/carbapenem combinations against
carbapenem-resistant Acinetobacter baumannii (CRAB) are largely unknown. Our objective …
被引用次数：54 相关文章 所有 10 个版本
[HTML] nih.gov

[HTML][HTML] Optimizing Treatment for Carbapenem-Resistant Acinetobacter baumannii Complex Infections: A Review of Current Evidence

SJ Choi, ES Kim - Infection & Chemotherapy, 2024 - ncbi.nlm.nih.gov
Carbapenem-resistant Acinetobacter baumannii complex (CRAB) poses a significant global
health challenge owing to its resistance to multiple antibiotics and limited treatment options …
相关文章 所有 4 个版本

Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections

SMS Lim, S Naicker, AK Ayfan, H Zowawi… - International journal of …, 2020 - Elsevier
Due to limited therapeutic options, combination therapy has been used empirically to treat
carbapenem-resistant Acinetobacter baumannii (CRAB). Polymyxin-based combinations …
被引用次数：11 相关文章 所有 7 个版本
[HTML] nature.com

[HTML][HTML] In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem …

YG Ju, HJ Lee, HS Yim, MG Lee, JW Sohn… - Scientific Reports, 2022 - nature.com
We investigated the in vitro activity of various antimicrobial combinations against
carbapenem-resistant Acinetobacter baumannii (CRAB) isolates. The in vitro activity of six …
被引用次数：17 相关文章 所有 11 个版本
[PDF] researchgate.net

Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii

S Chandran, Y Manokaran, S Vijayakumar… - European Journal of …, 2023 - Springer
Carbapenem-resistant Acinetobacter baumannii (CRAB) is often difficult to treat.
Considering the current circumstances, there is an unquestionable need for new therapeutic …
被引用次数：1 相关文章 所有 8 个版本

A carbapenem-resistant Acinetobacter baumannii outbreak associated with a polymyxin shortage during the COVID pandemic: an in vitro and biofilm analysis of …

V Chaiben, CH Yamada, JP Telles… - Journal of …, 2022 - academic.oup.com
Background During the COVID-19 pandemic, the burden of nosocomial infections caused by
MDR pathogens has caused a shortage of polymyxins. Thus, we evaluated the in vitro …
被引用次数：7 相关文章 所有 6 个版本
[PDF] tandfonline.com

In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii

H Zhang, Y Zhu, N Yang, Q Kong, Y Zheng… - Infection and Drug …, 2021 - Taylor & Francis
Purpose To study the in vitro and in vivo antibacterial activities of polymyxin B (PB) and other
five antimicrobial agents, including imipenem (IMP), meropenem (MEM), tigecycline (TGC) …
被引用次数：8 相关文章 所有 11 个版本